Direct demonstration of β1- and evidence against β2- and β3- adrenoceptors, in smooth muscle cells of rat small mesenteric arteries

被引:52
作者
Briones, AM
Daly, CJ
Jimenez-Altayo, F
Martinez-Revelles, S
Gonzalez, JM
McGrath, JC
Vila, E [1 ]
机构
[1] Univ Autonoma Barcelona, Fac Med, Inst Neurociencies, Dept Farmacol Terapeut & Toxicol, Bellaterra 08193, Spain
[2] Univ Glasgow, Fac Biomed & Life Sci, Div Neurosci & Biomed Sci, Glasgow G12 8QQ, Lanark, Scotland
关键词
adrenoceptors; beta-adrenoceptors; fluorescent ligands; imaging; vascular smooth muscle; mesenteric resistance artery;
D O I
10.1038/sj.bjp.0706369
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 Recent evidence supports additional subtypes of vasodilator beta-adrenoceptor (beta-AR) besides the 'classical' beta(2). The aim of this study was to investigate the distribution of beta-ARs in the wall of rat mesenteric resistance artery (MRA), to establish the relative roles of beta-ARs in smooth muscle and other cell types in mediating vasodilatation and to analyse this in relation to the functional pharmacology. 2 We first examined the vasodilator beta-AR subtype using 'subtype-selective' agonists against the, commonly employed, phenylephrine-induced tone. Concentration-related relaxation was produced by isoprenaline (pEC(50): 7.70 +/- 0.1) (beta(1) and beta(2)). Salbutamol (beta(2)), BRL 37344 (beta(3)) and CGP 12177 (atypical beta) caused relaxation but were 144, 100 and 263 times less potent than isoprenaline; the 'beta(3)-adrenoceptor agonist' CL 316243 was ineffective. 3 In arteries precontracted with 5-HT or U 46619, isoprenaline produced concentration-related relaxation but salbutamol, BRL 37344, CGP 12177 and CL 316243 did not. SR 59230A, CGP 12177 and BRL 37344 caused a parallel rightward shift in the concentration-response curve to phenylephrine indicating competitive alpha(1)-AR antagonism, explaining the false-positive 'vasodilator' action against phenylephrine-induced tone. Endothelial denudation but not L-NAME slightly attenuated isoprenaline-mediated vasodilatation in phenylephrine and U 46619 precontracted MRA. 4 The beta-AR fluorescent ligand BODIPY TMR-CGP 12177 behaved as an irreversible beta(1)-AR antagonist in MRA and bound to the surface and inside vascular smooth muscle cells in intact vascular wall. beta-ARs in smooth muscle cells were observed in a perinuclear location, consistent with the location of Golgi and endoplasmic reticulum. 5 Binding of BODIPY TMR-CGP 12177 was inhibited by BAAM (1 mu M) in all three vascular tunics, confirming the presence of beta-ARs in adventitia, media and intima. Binding in adventitia was observed in both neuronal and non- neuronal cell types. Lack of co-localisation with a fluorescent ligand for alpha-ARs confirms the selectivity of BODIPY TMR-CGP 12177 for beta-ARs over alpha-ARs. 6 Our results support the presence of functional vasodilator beta(1)-ARs and show that they are mainly located in smooth muscle cells. Furthermore, we have demonstrated, for the first time, the usefulness of BODIPY TMR-CGP 12177 for identifying beta-AR distribution in the 'living' vascular wall.
引用
收藏
页码:679 / 691
页数:13
相关论文
共 64 条
[1]  
Akimoto Yurie, 2002, Journal of Smooth Muscle Research, V38, P87, DOI 10.1540/jsmr.38.87
[2]   BETA(2)-ADRENOCEPTORS MEDIATE A REDUCTION IN ENDOTHELIAL PERMEABILITY IN-VITRO [J].
ALLEN, MJ ;
COLEMAN, RA .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 274 (1-3) :7-15
[3]   AUTORADIOGRAPHIC LOCALIZATION OF BETA-ADRENERGIC RECEPTORS IN HUMAN LARGE CORONARY-ARTERIES [J].
AMENTA, F ;
COPPOLA, L ;
GALLO, P ;
FERRANTE, F ;
FORLANI, A ;
MONOPOLI, A ;
NAPOLEONE, P .
CIRCULATION RESEARCH, 1991, 68 (06) :1591-1599
[4]   β3-adrenoceptor agonists:: potential, pitfalls and progress [J].
Arch, JRS .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 440 (2-3) :99-107
[5]   ATYPICAL BETA-ADRENOCEPTOR ON BROWN ADIPOCYTES AS TARGET FOR ANTI-OBESITY DRUGS [J].
ARCH, JRS ;
AINSWORTH, AT ;
CAWTHORNE, MA ;
PIERCY, V ;
SENNITT, MV ;
THODY, VE ;
WILSON, C ;
WILSON, S .
NATURE, 1984, 309 (5964) :163-165
[6]   BETA(3)-ADRENOCEPTOR AND ATYPICAL BETA-ADRENOCEPTOR [J].
ARCH, JRS ;
KAUMANN, AJ .
MEDICINAL RESEARCH REVIEWS, 1993, 13 (06) :663-729
[7]   The selectivity of β-adrenoceptor antagonists at the human β1, β2 and β3 adrenoceptors [J].
Baker, JG .
BRITISH JOURNAL OF PHARMACOLOGY, 2005, 144 (03) :317-322
[8]   Pharmacology and direct visualisation of BODIPY-TMR-CGP:: a long-acting fluorescent β2-adrenoceptor agonist [J].
Baker, JG ;
Hall, IP ;
Hill, SJ .
BRITISH JOURNAL OF PHARMACOLOGY, 2003, 139 (02) :232-242
[9]   DISODIUM (R,R)-5-[2-[[2-(3-CHLOROPHENYL)-2-HYDROXYETHYL]AMINO]PROPYL]-1,3-BENZODIOXOLE-2,2-DICARBOXYLATE (CL 316,243) - A POTENT BETA-ADRENERGIC AGONIST VIRTUALLY SPECIFIC FOR BETA-3 RECEPTORS - A PROMISING ANTIDIABETIC AND ANTIOBESITY AGENT [J].
BLOOM, JD ;
DUTIA, MD ;
JOHNSON, BD ;
WISSNER, A ;
BURNS, MG ;
LARGIS, EE ;
DOLAN, JA ;
CLAUS, TH .
JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (16) :3081-3084
[10]   α1-Adrenoceptor antagonist properties of CGP 12177A and other β-adrenoceptor ligands:: evidence against β3- or atypical β-adrenoceptors in rat aorta [J].
Brahmadevara, N ;
Shaw, AM ;
Macdonald, A .
BRITISH JOURNAL OF PHARMACOLOGY, 2004, 142 (04) :781-787